Abciximab

Research use only, not for human use.

Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor.

Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.

Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet αIIbβ3 integrin.Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them.

Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia.Animal Model:Male Wistar rats weighing 200-250 g, balloon angioplasty model Dosage:0.25 mg/kg/day Administration: Intravenous injection, 28 days Result:Time-dependently inhibited both neointimal hyperplasia and lumen occlusion after angioplasty in carotid arteries of rats. Significantly reduced PDGF-BB expression in vessel lumens and neointimal smooth muscle cells after angioplasty. Suppressed the elevation of plasma TxB2 concentration.

——

Cell Cycle/DNA Damage

Integrin

Integrin

——

——

143653-53-6

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years